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Abstract Aspartylglycosaminuria (AGU), a severe lysosomal
storage disease, is caused by the deficiency of the lysosomal
enzyme, glycosylasparaginase (GA), and accumulation of
aspartylglucosamine (GlcNAc-Asn) in tissues. Here we show
that human leukocyte glycosylasparaginase can correct the
metabolic defect in Epstein^Barr virus (EBV)-transformed
AGU lymphocytes rapidly and effectively by mannose-6-
phosphate receptor-mediated endocytosis or by contact-mediated
cell-to-cell transfer from normal EBV-transformed lymphocytes,
and that 2^7% of normal activity is sufficient to correct the
GlcNAc-Asn metabolism in the cells. Cell-to-cell contact is
obligatory for the transfer of GA since normal transformed
lymphocytes do not excrete GA into extracellular medium. The
combined evidence indicates that cell-to-cell transfer of GA plays
a main role in enzyme replacement therapy of AGU by normal
lymphocytes. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
Key words: Aspartylglucosylaminase; Bone marrow
transplantation; Cell-to-cell contact; Endocytosis;
Lysosomal storage disease
1. Introduction
Aspartylglycosaminuria (AGU, McKusick 208400) is the
most common disorder of glycoprotein degradation [1]. It is
caused by a de¢cient activity of the lysosomal enzyme glyco-
sylasparaginase (GA) (glycoasparaginase, aspartylglycosyl-
aminase, aspartylglucosaminidase, EC 3.5.1.26). GA is trans-
ported through a mannose-6-phosphate receptor-mediated
pathway from the endoplasmic reticulum or extracellular sites
into lysosomes, where it participates in the glycoprotein ca-
tabolism by cleaving the N-glycosidic linkage between N-ace-
tylglucosamine and L-asparagine [2]. De¢ciency of GA activity
in AGU cells leads to the accumulation of aspartylglucos-
amine (GlcNAc-Asn) and other glycoasparagines in body £u-
ids and tissues of AGU patients [3]. This recessively inherited
multisystem disease is characterized by progressive psychomo-
tor retardation, and structural abnormalities in the connective
tissue and skeleton [4].
Certain lysosomal enzymes are transferred from normal
lymphocytes to ¢broblasts from patients with lysosomal stor-
age diseases [5]. Lymphocytes can play an important role in
the transfer of corrective enzymes into cells throughout the
body in the treatment of lysosomal diseases by bone marrow
transplantation [6]. As a result of the presence of the donor
enzyme, clearance of the accumulating substrate, and repair of
damage and prevention of degenerative disease in the organs
a¡ected by the disease can be shown [7]. The transfer of ly-
sosomal enzymes can occur by two distinct mechanisms. One
is active internalization of the enzymes into lysosomes via
mannose-6-phosphate receptor-mediated endocytosis [8]. A
second, quite distinct process involves the transfer of certain
lysosomal enzymes from lymphocytes to enzyme-de¢cient cells
by cell-to-cell contact [5,7]. The e⁄cacy of bone marrow
transplantation to prevent and reverse the disease process
varies from one lysosomal disorder to another [7], suggesting
that complex and disease-speci¢c factors in transfer of di¡er-
ent lysosomal enzymes are involved. These include various
cellular or enzyme-related factors such as poor excretion of
enzymes out of normal lymphocytes, rapid degradation of the
enzyme protein during the transfer process, ine¡ective trans-
port of the enzyme into lysosomes of the recipient cells, rapid
degradation of the correcting enzyme in the target cells or the
requirement for a high intracellular enzyme activity to correct
the turnover of the lysosomal substrate.
Bone marrow transplantation has bene¢cial e¡ects on the
natural cause of AGU [9], but the factors that are involved
in the transfer of GA from normal to AGU cells and the
e⁄ciency of this process in correcting the metabolism in
the diseased cells are not fully understood. We have now
examined the transfer of human leukocyte GA from extra-
cellular medium and cell-to-cell from normal lymphocytes
to AGU lymphocytes and ¢broblasts in order to under-
stand the disease-speci¢c factors involved in the therapy of
AGU.
2. Materials and methods
2.1. Enzyme preparation and cell lines
Human leukocyte GA was puri¢ed 4600-fold (speci¢c activity 96
mU/mg protein) as described by [10]. Normal lymphocytes and ¢bro-
blasts were derived from a healthy person and the GA-de¢cient cells
from a Finnish AGU patient carrying the Cys163Ser mutation in the
GA gene [11]. Epstein^Barr virus (EBV)-transformed B-cell lines were
established as described by [12].
2.2. Treatment of AGU lymphocytes with puri¢ed leukocyte GA
EBV-transformed AGU lymphocytes (5^6U106) were cultured in
6 ml of RPMI/15% fetal calf serum (FCS) medium [2,12] for 10 days
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in the presence of various amounts of puri¢ed human leukocyte GA.
For biochemical analyses, 3^5U106 cells were withdrawn from the
culture, washed twice with phosphate-bu¡ered saline (PBS) and lysed
by freezing and thawing in 0.5 ml of 50 mM Na-K-phosphate, pH 7.2,
containing 0.1% Triton X-100.
The duration of the therapeutic e¡ect was studied by cultivation of
25U106 transformed AGU lymphocytes in the presence of 1000 mU/l
of human leukocyte GA in 30 ml of RPMI/15% FCS medium for 9 h,
after which 5U106 cells were collected and washed three times with
5 ml of PBS. Cultivation was continued in a culture medium in the
absence of GA supplementation for 13 days. 5U106 cells were with-
drawn from the culture on the day stated and they were treated for
the biochemical analyses as described above.
2.3. Co-cultivation of normal and AGU cells
A total of 10U106 transformed normal (female) and transformed
AGU (male) lymphocytes were co-cultured in a cell mixture originally
containing 20%, 40%, 60%, 80% or 100% of normal lymphocytes in
20 ml of RPMI/15% FCS medium for 10 days. 5 ml of the cell
suspension (2.5^10U106 cells) was withdrawn from the each culture
for biochemical analyses and another 5 ml for the determination of
the number of the Y-chromosome-containing (AGU) cells. 10 ml of
fresh medium was added. Cell-to-cell interaction was prevented by
culturing 2U106 transformed AGU lymphocytes and an equal
amount of transformed normal lymphocytes separated by a semi-per-
meable membrane (Nunc 25 mm tissue culture insert, 0.4 Wm poly-
carbonate membrane) in 8 ml of medium in a 6 well multidish. During
the culture, cell samples containing 1^4U106 cells were collected for
the biochemical analyses and treated as described above. An equiva-
lent volume of fresh medium was added. E¡ect of mannose-6-phos-
phate in the cell culture medium was studied by culturing 1U106
EBV-transformed normal lymphocytes with 4U106 transformed
AGU lymphocytes in 10 ml of RPMI/15% FCS medium in the pres-
ence of 5 mM mannose-6-phosphate (D-mannose-6-phosphate, Sigma
Chemical Co., St. Louis, MO, USA) for 10 days. 5 ml of the cell
suspension was withdrawn from the culture every second day for
the determination of GA activity. 5 ml of fresh M6P medium was
added.
Human AGU ¢broblasts were cultured [13] to near con£uence in a
9.2 cm Petri dish. 2U106 transformed AGU or transformed normal
lymphocytes were added to the ¢broblast culture in 20 ml RPMI/15%
FCS and the cultivation was continued for 6 days. Fibroblasts were
analyzed by immuno£uorescence microscopy.
2.4. Biochemical analyses and Y-chromosome hybridization assay
GA activity was measured with a £uorometric assay using L-(7-
amido-4-methylcoumarin)-L-aspartic acid (Bachem Feinchemikalien
AG, Bubendorf, Switzerland) as a substrate [14]. One unit of the
enzyme causes a loss of 1 Wmol of substrate per minute under
standard conditions. The GlcNAc-Asn amount in the cell homoge-
nates was determined by high-performance liquid chromatography
using carboxymethylcysteine (Sigma Chemical Co., St. Louis, MO,
USA) as an internal standard [15]. Protein concentration was
measured with the Bio-Rad protein assay kit (Bio-Rad Laborato-
ries, Richmond, CA, USA) according to the manufacturer’s instruc-
tions.
Y-chromosome-containing AGU lymphocytes were determined us-
ing Oncor Rapid In Situ Hybridization kit (Oncor, Inc., Gaithersburg,
MD, USA). Hybridization with a £uorescein-labeled Y-chromosome-
speci¢c DNA probe was performed according to the manufacturer’s
instructions.
2.5. Immuno£uorescence microscopy
After 6 days of co-cultivation of transformed normal lymphocytes
and AGU ¢broblasts, the cell culture medium and lymphocytes were
removed. The ¢broblasts were washed with PBS and incubated for 10
min in the presence of 100% methanol. The cells were washed with
PBS and treated with 1% Triton X-100 in PBS for 10 min [16]. The
permeabilized cells were blocked with fetal bovine serum and incu-
bated with a⁄nity-puri¢ed GA antibodies produced in hens [2]. After
washing with PBS, the cells were incubated with hen anti-rabbit anti-
bodies, washed with PBS and incubated with £uorescein isothiocya-
nate-conjugated anti-rabbit antibodies. After washing, the prepara-
tions were mounted with 50% glycerol in PBS containing 1% N-
propylgallate.
3. Results
3.1. Treatment of AGU lymphocytes with puri¢ed leukocyte
GA
Human leukocyte GA activity was relatively stable in the
cell culture medium at 37‡C with the half-life of 2.5 days (data
not shown). By incubation of EBV-transformed AGU lym-
phocytes in the presence of 300 mU/l of puri¢ed human leu-
kocyte GA in culture medium, the GA activity present in
transformed normal lymphocytes (17.7 WU/mg cell protein)
was attained in the diseased cells within 24 h (Fig. 1A) and
the concentration of GlcNAc-Asn in the cells was normalized
(Fig. 1B). When the culture medium contained 10^100 mU/l
of the leukocyte enzyme (Fig. 1A), the normal GA activity
was not achieved in the AGU cells, but the accumulation of
GlcNAc-Asn in them was prevented during a prolonged cul-
tivation (Fig. 1B). 10 mU/l of leukocyte GA in the medium
brought the GA activity in the AGU lymphocytes up to the
mean value of 0.8 WU/mg cell protein (0.3^1.3 WU/mg; n = 2)
(Fig. 1A) corresponding to 2^7% of the mean activity in nor-
mal lymphocytes (19.4 WU/mg cell protein, range 8.1^32.0 WU/
mg; n = 8) and the metabolism of GlcNAc-Asn in the cells
was completely corrected after 7 days of culture (Fig. 1B).
Cultivation of transformed AGU lymphocytes for 9 h in the
presence of 1000 mU/l of GA restored the GA activity in the
target cells to nearly the level present in normal lymphocytes
(Fig. 2A). When the cultivation was continued in the culture
Fig. 1. Uptake of human leukocyte GA by EBV-transformed AGU
lymphocytes and accumulation of GlcNAc-Asn in the cells. A: GA
activity in the cells during culture in media containing 0 mU/l (F),
10 mU/l (E), 30 mU/l (R), 100 mU/l (a), 300 mU/l (b) of leuko-
cyte GA (n = 1). GA activity in normal control lymphocytes cultured
without enzyme supplementation (dashed line). B: Intracellular ac-
cumulation of GlcNAc-Asn during culture in media containing
0 mU/l (F), 10 mU/l (E) and 100 mU/l (a) of leukocyte GA (n = 1).
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medium without GA supplementation, the intracellular GA
activity dropped from its highest value to the level of un-
treated cells within 7 days. The half-life of GA in transformed
AGU lymphocytes was estimated to be approximately 1 day.
The intracellular GlcNAc-Asn concentration was normalized
within the ¢rst 24 h of the experiment (Fig. 2B) and re-accu-
mulation of the compound was detected on day 4, when the
GA activity in the cells had decreased to 0.5 WU/mg cell pro-
tein. The concentration of GlcNAc-Asn reached the untreated
level in the cell mixture within 13 days of culture.
3.2. Treatment of AGU lymphocytes and ¢broblasts by
co-cultivation with normal lymphocytes
In a cell culture mixture, which contained 80% of trans-
formed normal and 20% of transformed AGU cells, the me-
tabolism of GlcNAc-Asn was completely corrected within 24 h
(Fig. 3). In the cell mixture, which originally contained 40%
of transformed AGU lymphocytes and 60% of transformed
normal cells, the GlcNAc-Asn metabolism was completely
normalized on the second day in culture (Fig. 3), in the pres-
ence of 65% of normal cells. In the cell pool, which contained
60% of transformed AGU lymphocytes in the beginning of the
experiment, the GlcNAc-Asn concentration decreased below
the detection limit (less than 0.3 nmol/mg cell protein) on day
8 (Fig. 3). Based on Y-chromosome assay, the cell pool con-
tained 65% of transformed normal cells at that time. In the
cell mixture, which initially contained 80% of transformed
AGU cells, a small amount of GlcNAc-Asn was still left in
the diseased cells on the tenth day of culture (Fig. 3), although
the proportion of transformed normal lymphocytes was in-
creased to 60%. The correction of the metabolic defect during
co-cultivation was not inhibited by 5 mM mannose-6-phos-
phate (Fig. 4). In a cell mixture, which contained 20% of
transformed normal and 80% of transformed AGU lympho-
cytes, the GA activity reached, on day 6, the level present in
normal lymphocytes in the presence or absence of 5 mM
mannose-6-phosphate (Fig. 4), indicating that mannose-6-
phosphate does not inhibit the correction of the GA activity.
When equal amounts of transformed AGU and trans-
formed normal lymphocytes were separated by a semi-perme-
able membrane and cultured for 10 days, no decrease in the
GlcNAc-Asn content (Fig. 3) was observed in the AGU cells.
The GA activity in the cell culture medium remained between
1.03 and 1.14 WU/ml indicating that lymphocytes do not ex-
crete signi¢cant amounts of the enzyme.
The transfer of GA from transformed normal lymphocytes
Fig. 2. GA activity and GlcNAc-Asn metabolism in EBV-trans-
formed AGU lymphocytes following treatment with leukocyte GA.
The transformed AGU cells were cultured for 9 h in the presence of
1000 mU/l of leukocyte GA. After washing, the cultivation of the
cells was continued in culture medium without GA supplementation.
A: GA activity. B: Accumulation of GlcNAc-Asn in the cells dur-
ing culture. GA-treated AGU lymphocytes (E), AGU lymphocytes
without enzyme treatment (F) and normal control lymphocytes
without enzyme treatment (dashed line) (n = 1).
Fig. 3. Correction of the metabolic defect in EBV-transformed
AGU lymphocytes and e¡ect of cell-to-cell interaction in the trans-
fer of GA to transformed AGU lymphocytes during co-cultivation
with EBV-transformed normal lymphocytes. Accumulation of
GlcNAc-Asn in the cell mixture during co-cultivation of normal and
AGU lymphocytes for the indicated times in medium containing
80% (E), 60% (R), 40% (a) or 20% (b) of AGU cells in the begin-
ning of the experiment (n = 1). The mean GlcNAc-Asn concentration
in transformed AGU lymphocytes which were separated from an
equal amount of transformed normal lymphocytes by a semi-perme-
able membrane during culture (O) compared to GlcNAc-Asn con-
tent in control AGU cells (F) (n = 2).
Fig. 4. E¡ect of mannose-6-phosphate on cell-to-cell transfer of
GA. EBV-transformed AGU lymphocytes were cultured with trans-
formed normal lymphocytes in the presence (F) or absence (E) of
5 mM mannose-6-phosphate for 10 days. Transformed normal lym-
phocytes (R) and AGU lymphocytes (O) without mannose-6-phos-
phate (n = 1).
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to AGU ¢broblasts during co-cultivation was studied by im-
munohistochemistry. After 6 days of co-cultivation, the pres-
ence of immunoreactive GA could be observed in the AGU
cells by immuno£uorescence microscopy (Fig. 5C). The im-
munoreactive GA showed a similar distribution pattern in the
treated cells as in normal human ¢broblasts (Fig. 5B,C), in-
dicating that GA had been predominantly targeted to the
lysosomes of the cells.
4. Discussion
The mannose-6-phosphate receptor-mediated endocytosis
[2] of exogenously administered human leukocyte GA e¡ec-
tively corrects the defect in glycoprotein metabolism in trans-
formed AGU lymphocytes. When the enzyme activity in
AGU cells is above 7% of that present in transformed normal
lymphocytes, accumulation of GlcNAc-Asn is prevented in
the diseased cells, which is comparable to the ¢ndings with
recombinant GA [2,17]. Treatment for 9 h with 1000 mU/l of
GA corrected the GlcNAc-Asn metabolism in the trans-
formed AGU cells within 24 h whereas re-accumulation of
the compound to the untreated level in the cells took almost
2 weeks. The high therapeutic e⁄cacy of leukocyte GA and
slow re-accumulation of GlcNAc-Asn in the treated cells are
encouraging ¢ndings for developing enzyme replacement ther-
apy for AGU.
AGU lymphocytes or ¢broblasts can also be treated by co-
cultivation with normal lymphocytes. The transfer of GA re-
quires cell-to-cell interaction to permit the exocytosis of the
correcting enzyme from normal lymphocytes with appropriate
endocytosis into abnormal ones. The mechanism of the direct
cell-to-cell transfer of GA does not involve mannose-6-phos-
phate receptor-mediated endocytosis, since it was not inhib-
ited by 5 mM mannose-6-phosphate. The comparable lack of
inhibition of mannose-6-phosphate has also been demon-
strated in cell-to-cell transfer of an other lysosomal enzyme,
L-glucuronidase [18]. The immuno£uorescence staining pat-
tern of GA in ¢broblasts acquired by cell-to-cell transfer
was similar to that of normal GA transfected in COS-1 or
CHO ¢broblasts [19,20], indicating that the enzyme is pre-
dominantly targeted to the lysosomes of AGU ¢broblasts
and that mannose-6-phosphate receptor-mediated transport
might be involved inside the cells to take the enzyme into
lysosomes. The cell-to-cell transferred GA is catalytically ac-
tive and degrades the storage compound in the recipient AGU
lymphocytes. The e⁄cacy of the cell-to-cell transfer of GA in
the correction of the metabolic defect in those cells is related
to the proportion of normal lymphocytes in the cell mixture,
since normal lymphocytes do not excrete GA outside of cells.
The precise mechanism of the contact-mediated enzyme
transfer is not clear. It is known that cell contact involves
speci¢c adhesion molecules, which can evoke di¡erent cellular
activation pathways. It is suggested that cell-to-cell contact
induces synthesis of new lysosomal enzyme precursors, which
are subsequently transferred to the recipient cells in non-
coated vesicles through the endocytic pathway [21]. The direct
transfer of enzymes via cell-to-cell contact is restricted to only
certain lysosomal enzymes [22]. Although the transfer of lyso-
somal enzymes via direct cell contact is the mechanism mostly
utilized by cell types which do not secrete enzymes, it is also
used by cells secreting the enzymes in addition to the receptor-
mediated uptake [18]. The contact-mediated transfer of lyso-
somal enzymes from lymphocytes has an important role in
enzyme replacement therapy by bone marrow transplantation
of lysosomal diseases [6,23]. This applies also to AGU, since a
technically successful bone marrow transplantation has bene-
¢cial e¡ects on the natural cause of the disease [9].
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